Figure 4

Inhibitory effect of the mTOR inhibitor, everolimus, in 4-NQO-induced tongue cancer murine model. (A) The incidence of tongue papilloma in mice treated with placebo, low dose everolimus, and high dose everolimus. There were no significant differences in papilloma between three groups. (B) The incidence of tongue SCC in mice treated with placebo, low dose everolimus, and high dose everolimus. Mice in high dose everolimus group developed significantly (P = 0.041) less invasive SCC than those in vehicle group. (C) Gross appearance and hematoxylin and eosin stained (H and E) sections of normal tongue, tongue papilloma, and tongue SCC from representative mice. Original magnification × 200. SCC: squamous cell carcinoma.